{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:36:45Z","timestamp":1790030205922,"version":"4.0.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ebiom.2022.104264","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T01:48:45Z","timestamp":1664329725000},"page":"104264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5466-0897","authenticated-orcid":false,"given":"Bhargava","family":"Kandala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2025-4441","authenticated-orcid":false,"given":"Nele","family":"Plock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-3901","authenticated-orcid":false,"given":"Akshita","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Largajolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Robey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenny","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Thatavarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri A.","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y. Amy","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"de Greef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5725-558X","authenticated-orcid":false,"given":"Jeffrey R.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104264_bib0001","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104264_bib0002","doi-asserted-by":"crossref","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against sars-cov-2 in nonhuman primates","volume":"373","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104264_bib0003","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1038\/s41467-021-26117-x","article-title":"SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques","volume":"12","author":"Roozendaal","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2022.104264_bib0004","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.104264_bib0005","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2022.104264_bib0006","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.104264_bib0007","doi-asserted-by":"crossref","unstructured":"Padmanabhan P, Desikan R, and Dixit NM. 2021. Modelling the population-level protection conferred by covid-19 vaccination. medRxiv. 2021.2003.2016.21253742. https:\/\/doi.org\/10.1101\/2021.03.16.21253742","DOI":"10.1101\/2021.03.16.21253742"},{"key":"10.1016\/j.ebiom.2022.104264_bib0008","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1002\/cpt.1462","article-title":"Model-based meta-analysis: optimizing research, development, and utilization of therapeutics using the totality of evidence","volume":"106","author":"Upreti","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2022.104264_bib0009","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(21)00306-8","article-title":"Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment","volume":"397","author":"Wouters","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104264_bib0010","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1126\/science.abm0620","article-title":"SARS-CoV-2 vaccine protection and deaths among us veterans during 2021","volume":"375","author":"Cohn","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104264_bib0011","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104264_bib0012","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104264_bib0013","doi-asserted-by":"crossref","unstructured":"van Doremalen N, Purushotham JN, Schulz JE, et al. Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques. bioRxiv. 2021:2021.2001.2009.426058. https:\/\/doi.org\/10.1101\/2021.01.09.426058","DOI":"10.1101\/2021.01.09.426058"},{"key":"10.1016\/j.ebiom.2022.104264_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103651","article-title":"Forward and reverse translational approaches to predict efficacy of neutralizing respiratory syncytial virus (RSV) antibody prophylaxis","volume":"73","author":"Maas","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2022.104264_bib0015","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/psp4.12679","article-title":"V2ACHER: visualization of complex trial data in pharmacometric analyses with covariates","volume":"10","author":"Lommerse","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.ebiom.2022.104264_bib0016","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104264_bib0017","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.abc4776","article-title":"SARS-CoV-2 infection protects against rechallenge in rhesus macaques","volume":"369","author":"Chandrashekar","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104264_bib0018","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104264_bib0019","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1016\/j.vaccine.2020.10.064","article-title":"NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge","volume":"38","author":"Guebre-Xabier","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2022.104264_bib0020","doi-asserted-by":"crossref","unstructured":"Patel A, Walters J, Reuschel EL, et al. Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model. bioRxiv. 2020:2020.2007.2028.225649. https:\/\/doi.org\/10.1101\/2020.07.28.225649","DOI":"10.1101\/2020.07.28.225649"},{"key":"10.1016\/j.ebiom.2022.104264_bib0021","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104264_bib0022","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2022.104264_bib0023","doi-asserted-by":"crossref","unstructured":"Rauch S, Gooch K, Hall Y, et al. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. bioRxiv. 2020:2020.2012.2023.424138. https:\/\/doi.org\/10.1101\/2020.12.23.424138","DOI":"10.1101\/2020.12.23.424138"},{"key":"10.1016\/j.ebiom.2022.104264_bib0024","doi-asserted-by":"crossref","unstructured":"Furuyama W, Shifflett K, Pinski AN, et al. Rapid protection from COVID-19 in nonhuman primates vaccinated intramuscularly but not intranasally with a single dose of a recombinant vaccine. bioRxiv 2021.01.19.426885. https:\/\/doi.org\/10.1101\/2021.01.19.426885","DOI":"10.1101\/2021.01.19.426885"},{"key":"10.1016\/j.ebiom.2022.104264_bib0025","doi-asserted-by":"crossref","unstructured":"Brouwer PJM, Brinkkemper M, Maisonnasse P, et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2infection. bioRxiv. 2020:2020.2011.2007.365726. https:\/\/doi.org\/10.1101\/2020.11.07.365726","DOI":"10.1101\/2020.11.07.365726"},{"key":"10.1016\/j.ebiom.2022.104264_bib0026","series-title":"Pfizer-BioNTech COVID-19 Vaccine (BNT162, PF-07302048) Vaccines and Related Biological Products Advisory Committe Briefing Document","year":"2020"},{"key":"10.1016\/j.ebiom.2022.104264_bib0027","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104264_bib0028","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104264_bib0029","series-title":"mRNA-1273 Sponsor Briefing Document Vaccines and Related Biological Products Advisory Committee","year":"2020"},{"key":"10.1016\/j.ebiom.2022.104264_bib0030","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.vaccine.2021.02.007","article-title":"A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine","volume":"39","author":"Chu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ebiom.2022.104264_bib0031","series-title":"COVID-19 Vaccine Ad26.COV2.S VAC31518 (JNJ-78436735) Sponsor Briefing Document Vaccines and Related Biological Products Advisory Committee","year":"2021"},{"key":"10.1016\/j.ebiom.2022.104264_bib0032","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104264_bib0033","doi-asserted-by":"crossref","unstructured":"Formica N, Mallory R, Albert G, et al. Evaluation of a SARS-CoV-2 Vaccine NVX-CoV2373in younger and older adults. medRxiv. 2021:2021.2002.2026.21252482. https:\/\/doi.org\/10.1101\/2021.02.26.21252482","DOI":"10.1101\/2021.02.26.21252482"},{"key":"10.1016\/j.ebiom.2022.104264_bib0034","series-title":"Efficacy Data Updates from Novavax\u2019 Protein-Based Vaccine Candidate","year":"2021"},{"key":"10.1016\/j.ebiom.2022.104264_bib0035","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104264_bib0036","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","article-title":"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia","volume":"396","author":"Logunov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104264_bib0037","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104264_bib0038","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104264_bib0039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","article-title":"Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial","volume":"21","author":"Zhang","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104264_bib0040","series-title":"Summary of Clinical Trial Data of Sinovac's COVID-19 Vaccine (CoronaVac\u00ae)","year":"2021"},{"key":"10.1016\/j.ebiom.2022.104264_bib0041","doi-asserted-by":"crossref","unstructured":"Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial. medRxiv. 2021:2021.2006.2030.21259439. https:\/\/doi.org\/10.1101\/2021.06.30.21259439","DOI":"10.1101\/2021.06.30.21259439"},{"key":"10.1016\/j.ebiom.2022.104264_bib0042","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial","volume":"21","author":"Ella","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104264_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.06.020","article-title":"Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum","volume":"184","author":"Liu","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2022.104264_bib0044","doi-asserted-by":"crossref","unstructured":"Cromer D, Steain M, Reynaldi A, et al. SARS-CoV-2 variants: levels of neutralisation required for protective immunity. medRxiv2021:2021.2008.2011.21261876. https:\/\/doi.org\/10.1101\/2021.08.11.21261876","DOI":"10.1101\/2021.08.11.21261876"},{"key":"10.1016\/j.ebiom.2022.104264_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104138","article-title":"Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 Vaccine) in healthy adults: results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial","volume":"82","author":"Robbins","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2022.104264_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103811","article-title":"Safety and immunogenicity of measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1\/2 randomized, double-blind, placebo-controlled, dose ranging trial","volume":"75","author":"Vanhoutte","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2022.104264_bib0047","series-title":"American Conference of Pharmacometrics (ACoP). Virtual","article-title":"(lost in) translation: Rodent modeling and validation with mbma","author":"Lommerse","year":"2021"},{"key":"10.1016\/j.ebiom.2022.104264_bib0048","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41591-020-0868-6","article-title":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes","volume":"26","author":"Sungnak","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.104264_bib0049","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10928-010-9151-7","article-title":"Basic PK\/PD principles of drug effects in circular\/proliferative systems for disease modelling","volume":"37","author":"Jacqmin","year":"2010","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ebiom.2022.104264_bib0050","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1214\/14-AOS1240","article-title":"Optimal cross-validation in density estimation with the L2-loss","volume":"42","author":"Celisse","year":"2014","journal-title":"Ann Stat"},{"key":"10.1016\/j.ebiom.2022.104264_bib0051","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ebiom.2022.104264_bib0052","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104264_bib0053","unstructured":"Novavax. Novavax announces initial Omicron cross-reactivity data from COVID-19 vaccine booster and adolescent studies. 2021. Available at: https:\/\/ir.novavax.com\/2021-12-22-Novavax-Announces-Initial-Omicron-Cross-Reactivity-Data-from-COVID-19-Vaccine-Booster-and-Adolescent-Studies. Accessed 2 February 2022."},{"key":"10.1016\/j.ebiom.2022.104264_bib0054","doi-asserted-by":"crossref","unstructured":"Chen X, Wang W, Chen X, et al. Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 delta variant by clinical endpoint. medRxiv. 2021:2021.09.23.21263715 https:\/\/doi.org\/10.1101\/2021.09.23.21263715","DOI":"10.1101\/2021.09.23.21263715"},{"key":"10.1016\/j.ebiom.2022.104264_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00527-21","article-title":"Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays","volume":"59","author":"Sholukh","year":"2021","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ebiom.2022.104264_bib0056","series-title":"Establishment of the WHO International Standard and Reference Panel for Anti-SARS-CoV-2 Antibody","author":"Mattiuzzo","year":"2020"},{"key":"10.1016\/j.ebiom.2022.104264_bib0057","series-title":"Clinical Development & Operations and Enabling Sciences SWAT Teams","article-title":"COVID-19: correlates of protection","year":"2020"},{"key":"10.1016\/j.ebiom.2022.104264_bib0058","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s43588-022-00198-0","article-title":"Modeling how antibody responses may determine the efficacy of covid-19 vaccines","volume":"2","author":"Padmanabhan","year":"2022","journal-title":"Nat Comput Sci"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422004467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422004467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:20:07Z","timestamp":1762456807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422004467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":58,"alternative-id":["S2352396422004467"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104264","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104264","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104264"}}